The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial

Abstract Background The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events—Aspirin (ACTIVE-A) demonstrated that in patients with atrial fibrillation unsuitable for vitamin K antagonist (VKA) therapy, a combination of clopidogrel and aspirin reduced stroke risk by...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Canadian journal of cardiology 2012, Vol.28 (1), p.95-101
Hauptverfasser:	Lamy, Andre, MD, MHSc, Tong, Wesley, BSc (Hons), Gao, Peggy, MSc, Chrolavicius, Susan, BScN, Gafni, Amiram, PhD, Yusuf, Salim, DPhil, Connolly, Stuart J., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Atrial Fibrillation - drug therapy Atrial Fibrillation - economics Canada Cardiovascular Cost-Benefit Analysis Drug Costs - statistics & numerical data Follow-Up Studies Health Care Costs Humans Platelet Aggregation Inhibitors - economics Platelet Aggregation Inhibitors - therapeutic use Ticlopidine - analogs & derivatives Ticlopidine - economics Ticlopidine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!